Drug Guide
Isoniazid, Pyrazinamide, Rifampin
Classification
Therapeutic: Antitubercular agents
Pharmacological: Combination antimycobacterial agents
FDA Approved Indications
- Latent tuberculosis infection and active tuberculosis
Mechanism of Action
Isoniazid inhibits Mycobacterium tuberculosis synthesis of mycolic acids, essential components of the bacterial cell wall. Pyrazinamide disrupts membrane transport and energy production in the bacteria. Rifampin inhibits DNA-dependent RNA polymerase in bacteria, suppressing RNA synthesis.
Dosage and Administration
Adult: As per TB treatment guidelines, typically once daily or twice weekly, depending on regimen; specific dosages depend on weight and disease severity.
Pediatric: Dosing based on weight, typically 10-20 mg/kg for Isoniazid, 25-35 mg/kg for Pyrazinamide, and 10 mg/kg for Rifampin.
Geriatric: Use with caution; monitor for hepatic function, as risk of hepatotoxicity increases.
Renal Impairment: Adjustments may be necessary, especially for Pyrazinamide.
Hepatic Impairment: Use cautiously; monitor liver function regularly.
Pharmacokinetics
Absorption: Well absorbed orally
Distribution: Wide distribution, including cerebrospinal fluid (CSF) especially with meningeal inflammation
Metabolism: Isoniazid mainly hepatic; Rifampin hepatic; Pyrazinamide hepatic and renal
Excretion: Urine primarily; Rifampin also excreted in bile
Half Life: Isoniazid: 1-4 hours; Rifampin: 3-5 hours; Pyrazinamide: 9-10 hours
Contraindications
- History of hypersensitivity to any of the components
Precautions
- Hepatic impairment, alcohol use, pre-existing liver disease; monitor liver enzymes regularly.
Adverse Reactions - Common
- Hepatotoxicity (Uncommon but serious, can be severe)
- Peripheral neuropathy (more with Isoniazid) (Common)
- Gastrointestinal discomfort (Common)
- Rash (Uncommon)
Adverse Reactions - Serious
- Disseminated or fulminant hepatitis (Rare)
- Optic neuritis (with high doses of Isoniazid) (Rare)
- Allergic reactions such as rash, eosinophilia (Uncommon)
Drug-Drug Interactions
- Alcohol (increases hepatotoxicity risk), other hepatotoxic drugs, oral contraceptives (may decrease efficacy)
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Monitor liver function tests, complete blood counts, and for signs of hepatotoxicity; assess for symptoms of peripheral neuropathy.
Diagnoses:
- Impaired skin integrity related to hypersensitivity reactions
- Risk for hepatotoxicity
Implementation: Administer as prescribed; monitor for adverse effects; provide pyridoxine (vitamin B6) to prevent peripheral neuropathy with Isoniazid.
Evaluation: Lack of adverse effects; resolution of TB symptoms; normal liver function tests.
Patient/Family Teaching
- Take medications exactly as prescribed.
- Report symptoms of liver problems (fatigue, weakness, nausea, jaundice).
- Avoid alcohol and hepatotoxic drugs.
- Complete entire course of therapy to prevent resistance.
Special Considerations
Black Box Warnings:
- Hepatotoxicity, especially in older adults and those with pre-existing liver disease
Genetic Factors: Slow acetylators of Isoniazid may have increased risk of toxicity.
Lab Test Interference: False-positive urine scans for opiates with Rifampin.
Overdose Management
Signs/Symptoms: Hepatic failure, hypersensitivity, neurotoxicity with Isoniazid overdose.
Treatment: Supportive care, activated charcoal if recent ingestion, monitor liver function, pyridoxine (vitamin B6) for Isoniazid overdose.
Storage and Handling
Storage: Store at room temperature, away from moisture and light.
Stability: Stable under proper storage conditions.